Breast cancer biosimilar approval delayed as US FDA reviews additional information by Biocon, Mylan Industry-The Economic Times — August 30, 2017 comments off Biocon and Mylan have together developed the trastuzumab biosimilar, which is a copy of a complex biologic drug developed by Swiss biotech giant Roche.